This week, there are many new changes in the executives of pharmaceutical companies

Since the beginning of this year, more than one hundred executives in the pharmaceutical industry have resigned
.
Among them, in the first half of November alone, there were personnel changes in the executives of more than 18 companies, involving Pfizer, AstraZeneca, Ascent Pharmaceuticals, WuXi Biologics, Sinopharm, Kangzhi Pharmaceutical, Jinshi Yayao, Hengrui Pharmaceuticals, Lexin Medical and other domestic and foreign pharmaceutical companies
.
On the whole, there are many senior executives such as the chairman and general manager
.
It is worth noting that there have been new changes in many pharmaceutical company executives this week
.
Hebo Medicine Appoints New Chief Strategy Officer On December 3, it was learned that Hebo Medicine announced that it had formally appointed Xu Weihao as Chief Strategy Officer, reporting directly to Dr.
Wang Jinsong, the founder, chairman and CEO of Hebo Medicine
.
As the company's global head of business development and corporate development, Xu Weihao will be responsible for the strategy formulation, innovation capability expansion, and innovation ecosystem construction of Hebo Pharmaceutical to promote the company's development
.
At the same time, he will also participate in the company's product line strategy and the expansion of investor relations in the international market
.
It is understood that Hebo Pharmaceutical is a global biopharmaceutical company focusing on the research and development and commercialization of innovative drugs in the field of tumors and immune diseases
.
The company rapidly expands its innovative drug research and development pipeline through independent research and development, joint development and diversified cooperation models
.
The industry believes that Mr.
Xu Weihao's experience in global capital markets, equity investment and financial management is expected to play an important role in the formulation of corporate strategies for Hebo Pharma in the future
.
The President of Fresenius Kabi China will leave office in February next year.
On December 2, Fresenius Kabi issued an internal notice: Mr.
Ding Weibo, President of Feka China, has decided to accept external development opportunities and will be formally announced on February 1, 2022.
Leave office
.
According to the data, Fresenius Kabi is a very professional and outstanding multinational pharmaceutical company in the pharmaceutical market segment-infusion, blood transfusion and clinical nutrition.
Its business covers pharmaceuticals, nutrition and medical devices.

.
Mr.
Ding Weibo joined Fresenius Kabi in 2015.
Prior to that, he had worked for Novartis China for many years and held various positions including General Manager of Business Unit, General Manager of North China, and President of Novartis Vaccine China
.
It is reported that Mr.
UlfJansson, Executive Vice President of Fresenius Kabi Asia Pacific, will concurrently serve as the President of Fresenius Kabi China, and will complete the handover with Mr.
Ding Weibo before the end of January next year
.
Since the beginning of this year, Fresenius Kabi has actually made many adjustments in the appointment, operation and development of senior management.
On March 16, Fresenius Kabi announced the appointment of Michael Sen from Siemens Medical as the new CEO; Last month, Fresenius Kabi also announced a new vision for 2026 and a new organizational structure for 2022
.
Fuhong Henlius appoints Zhang Wenjie as chairman of the board.
On November 30, Fuhong Henlius announced that Chen Qiyu had resigned as chairman of the company due to adjustments in work arrangements.
After resignation, Chen Qiyu will still serve as a non-executive director of Fuhong Henlius
.
At the same time, the company nominates the current executive director, chief executive officer and president Zhang Wenjie as chairman and chief executive officer, who will lead the management team to conduct daily management of the company and supervise the operation of the company and its subsidiaries
.
Mr.
Zhu Jun, the current Chief Medical Officer and Senior Vice President, takes over as President and is responsible for the company's global product development and management of some functional departments
.
It is understood that Zhang Wenjie has more than 20 years of commercial operation experience in the pharmaceutical industry
.
From 2010 to 2014, Zhang Wenjie served as the vice president of the second oncology business department of Shanghai Roche Pharmaceuticals Co.
, Ltd.
, and led approximately 850 employees including marketing and sales.
He also worked in the US branch of Bayer Pharmaceutical Engineering and successively served as the product of the US marketing department.
manager, business development manager and vice president of global marketing and so on
.
Before joining Fuhong Henlius in March 2019, Zhang Wenjie was the general manager of Amgen in China, responsible for the business expansion of Amgen in China.

.
In addition, Mr.
Zhu Jun has focused on the field of clinical development for more than 20 years.
He has led the design and execution of more than 100 clinical trials, and has achieved significant results in multiple therapeutic fields.
He has rich industry experience and profound knowledge of innovative research and development.
Understanding is expected to help Fuhong Henlius to further deepen the value of its product pipeline
.